

The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F COVER PAGE

OMB APPROVAL

OMB Number:	3235-0006
Expires:	Oct 31, 2018
Estimated average burden hours per response:	23.8

Report for the Calendar Year or Quarter Ended: 09-30-2022

Check here if Amendment Amendment Number: _____
This Amendment (Check only one.): is a restatement.
 adds new holdings entries.

Institutional Investment Manager Filing this Report:

Name: JOHNSON & JOHNSON
Address: ONE JOHNSON & JOHNSON PLZ
NEW BRUNSWICK, NJ 08933

Form 13F File Number: 028-20072

The institutional investment manager filing this report and the person by whom it is signed hereby represent that the person signing the report is authorized to submit it, that all information contained herein is true, correct and complete, and that it is understood that all required items, statements, schedules, lists, and tables, are considered integral parts of this form.

Person Signing this Report on Behalf of Reporting Manager:

Name: Marc Larkins
Title: Secretary
Phone: 732-524-1476

Signature, Place, and Date of Signing:

/s/ Marc Larkins New Brunswick, NJ 11-10-2022
[Signature] [City, State] [Date]

Report Type (Check only one.):

13F HOLDINGS REPORT. (Check here if all holdings of this reporting manager are reported in this report.)

13F NOTICE. (Check here if no holdings reported are in this report, and all holdings are reported by other reporting manager(s).)

13F COMBINATION REPORT. (Check here if a portion of the holdings for this reporting manager are reported in this report and a portion are reported by other reporting manager(s).)

Form 13F Summary Page

Report Summary:

Number of Other Included Managers:	2
Form 13F Information Table Entry Total:	22
Form 13F Information Table Value Total:	339,823

(thousands)

List of Other Included Managers:

Provide a numbered list of the name(s) and Form 13F file number(s) of all institutional investment managers with respect to which this report is filed, other than the manager filing this report.

[If there are no entries in this list, state "NONE" and omit the column headings and list entries.]

No.	Form 13F File Number	Name
1	028-20073	Johnson & Johnson Innovation - JJDC, Inc.
2	028-21422	Johnson & Johnson UK Treasury Co Ltd

The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE

OMB APPROVAL	
OMB Number:	3235-0006
Expires:	Oct 31, 2018
Estimated average burden hours per response:	23.8

COLUMN 1 NAME OF ISSUER	COLUMN 2 TITLE OF CLASS	COLUMN 3 CUSIP	COLUMN 4 VALUE (x\$1000)	COLUMN 5			COLUMN 6 INVESTMENT DISCRETION	COLUMN 7 OTHER MANAGER	COLUMN 8		
				SHRS OR PRN AMT	SH/ PUT/ CALL				SOLE	SHARED	NONE
Adicet Bio, Inc.	COM	007002108	10,366	728,944	SH		DFND	1	0	728,944	0
Aldeyra Therapeutics, Inc.	COM	01438T106	2,108	394,834	SH		DFND	1	0	394,834	0
Arrowhead Pharmaceuticals, Inc.	COM	04280A100	8,183	247,598	SH		DFND	1	0	247,598	0
BiomX Inc.	COM	09090D103	725	2,133,402	SH		DFND	1	0	2,133,402	0
Catalyst Biosciences, Inc.	COM	14888D208	34	66,951	SH		DFND	1	0	66,951	0
Cue Health, Inc.	COM	229790100	16,702	5,548,864	SH		DFND	1	0	5,548,864	0
CVRx, Inc.	COM	126638105	32,614	3,495,575	SH		DFND	1	0	3,495,575	0
Fate Therapeutics, Inc.	COM	31189P102	75,725	3,379,064	SH		DFND	1	0	3,379,064	0
Fusion Pharmaceuticals Inc.	COM	36118A100	11,048	3,670,516	SH		DFND	1	0	3,670,516	0
Graybug Vision, Inc.	COM	38942Q103	47	49,547	SH		DFND	1	0	49,547	0
Legend Biotech Corporation	ADS	52490G102	66,470	1,629,173	SH		DFND	1	0	1,629,173	0
MeiraGTx Holdings plc	COM	G59665102	24,377	2,898,550	SH		DFND	1	0	2,898,550	0
Nano-X Imaging Ltd.	ORD SHS	M70700105	2,207	192,429	SH		DFND	1	0	192,429	0
PhaseBio Pharmaceuticals, Inc.	COM	717224109	283	1,607,044	SH		DFND	1	0	1,607,044	0
Point Biopharma Global Inc.	COM	730541109	7,730	1,000,000	SH		DFND	1	0	1,000,000	0
Procept BioRobotics Corporation	COM	74276L105	35,818	863,908	SH		DFND	1	0	863,908	0
Protagonist Therapeutics Inc.	COM	74366E102	20,647	2,449,183	SH		DFND	1	0	2,449,183	0
Senseonics Holdings, Inc.	COM	81727U105	72	54,621	SH		DFND	1	0	54,621	0
Tracon Pharmaceuticals,	COM	89237H209	140	84,003	SH		DFND	1	0	84,003	0

Inc.										
Vor Biopharma, Inc.	COM	929033108	4,277	1,074,658	SH	DFND	1	0	1,074,658	0
Xencor, Inc.	COM	98401F105	19,435	748,062	SH	DFND	1	0	748,062	0
SomaLogic, Inc.	COM	83444K105	815	281,052	SH	DFND	N/A	0	281,052	0